COLL (Collegium Pharmaceutical, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by COLL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-10 | GINO SANTINI | Director | M | — | — |
| 2026-05-20 | John Gordon Freund | Director | Sell | — | — |
| 2026-05-18 | GAREN G BOHLIN | Director | A | — | — |
| 2026-05-18 | Carlos V Paya | Director | A | — | — |
| 2026-05-18 | Donovan Michael Glancy | Director | A | — | — |
| 2026-05-18 | GINO SANTINI | Director | A | — | — |
| 2026-05-18 | Rita J. Balice-Gordon | Director | A | — | — |
| 2026-05-18 | Nancy Lurker | Director | A | — | — |
| 2026-05-18 | John Gordon Freund | Director | MIXED | — | — |
| 2026-05-15 | Nancy Lurker | Director | Sell | — | — |
| 2026-05-13 | GAREN G BOHLIN | Director | MIXED | — | — |
| 2026-04-03 | David Dieter | EVP & General Counsel | F | — | — |
| 2026-03-20 | David Dieter | EVP & General Counsel | Sell | — | — |
| 2026-03-11 | David Dieter | EVP & General Counsel | Sell | — | — |
| 2026-03-05 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | — | — |
| 2026-02-12 | Thomas B Smith | EVP and Chief Medical Officer | MIXED | — | — |
| 2026-02-12 | Vikram Karnani | President and CEO | MIXED | — | — |
| 2026-02-12 | Scott Dreyer | EVP & Chief Commercial Officer | MIXED | — | — |
| 2026-02-12 | David Dieter | EVP & General Counsel | MIXED | — | — |
| 2026-02-12 | Colleen Tupper | EVP & Chief Financial Officer | MIXED | — | — |
| 2025-12-10 | Scott Dreyer | EVP & Chief Commercial Officer | MIXED | — | — |
| 2025-12-09 | Rita J. Balice-Gordon | Director | Sell | — | — |
| 2025-11-14 | Vikram Karnani | President and CEO | F | — | — |
| 2025-11-14 | John A. Fallon | Director | MIXED | — | — |
| 2025-11-07 | Colleen Tupper | EVP & Chief Financial Officer | Sell | — | — |
| 2025-09-03 | Thomas B Smith | EVP and Chief Medical Officer | Sell | — | — |
| 2025-08-20 | Scott Dreyer | EVP & Chief Commercial Officer | MIXED | — | — |
| 2025-08-19 | GINO SANTINI | Director | MIXED | — | — |
| 2025-08-15 | Rubric Capital Management LP | 10%+ Owner | Sell | — | — |
| 2025-08-15 | Scott Dreyer | EVP & Chief Commercial Officer | MIXED | — | — |
| 2025-08-12 | John Gordon Freund | Director | Sell | — | — |
| 2025-06-11 | John Gordon Freund | Director | MIXED | — | — |
| 2025-05-19 | Carlos V Paya | Director | A | — | — |
| 2025-05-19 | John A. Fallon | Director | A | — | — |
| 2025-05-19 | GINO SANTINI | Director | A | — | — |
| 2025-05-19 | Nancy Lurker | Director | A | — | — |
| 2025-05-19 | Rita J. Balice-Gordon | Director | A | — | — |
| 2025-05-19 | John Gordon Freund | Director | A | — | — |
| 2025-05-19 | GAREN G BOHLIN | Director | A | — | — |
| 2025-03-24 | Colleen Tupper | EVP & Chief Financial Officer | Sell | — | — |
| 2025-03-24 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | — | — |
| 2025-03-19 | David Dieter | EVP & General Counsel | A | — | — |
| 2025-03-18 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | — | — |
| 2025-03-18 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | — | — |
| 2025-03-18 | Colleen Tupper | EVP & Chief Financial Officer | Sell | — | — |
| 2025-03-13 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | — | — |
| 2025-03-13 | Colleen Tupper | EVP & Chief Financial Officer | Sell | — | — |
| 2025-03-10 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | — | — |
| 2025-03-10 | Colleen Tupper | EVP & Chief Financial Officer | Sell | — | — |
| 2025-03-06 | Shirley R. Kuhlmann | EVP and General Counsel | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,029,785 | — |
| — | 10%+ Owner | 6,020,410 | — |
| — | 10%+ Owner | 3,132,743 | — |
| — | 10%+ Owner | 2,799,916 | — |
| — | — | 1,325,253 | — |
| — | 10%+ Owner | 1,196,834 | — |
| — | Director | 1,196,834 | — |
| — | 10%+ Owner | 525,634 | — |
| — | President and CEO | 444,867 | — |
| — | President and CEO | 370,297 | — |
| — | 10%+ Owner | 235,020 | — |
| — | Executive Vice President & CFO | 215,428 | — |
| — | Director | 213,371 | — |
| — | President and CEO | 209,160 | — |
| — | EVP & Chief Financial Officer | 185,822 | — |
| — | EVP & Chief Technical Officer | 143,694 | — |
| — | EVP and Chief Medical Officer | 136,564 | — |
| — | EVP and General Counsel | 134,204 | — |
| — | Director | 112,483 | — |
| — | Director | 107,081 | — |
| — | Director | 99,487 | — |
| — | EVP and Chief Medical Officer | 90,651 | — |
| — | Director | 82,504 | — |
| — | EVP & Chief Commercial Officer | 75,329 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the COLL quote page; the site-wide leaderboard is on the insider transactions hub.